Compare UPWK & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UPWK | COLL |
|---|---|---|
| Founded | 1998 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.2B |
| IPO Year | 2018 | 2015 |
| Metric | UPWK | COLL |
|---|---|---|
| Price | $11.11 | $33.53 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 5 |
| Target Price | $22.73 | ★ $51.40 |
| AVG Volume (30 Days) | ★ 2.9M | 496.0K |
| Earning Date | 05-04-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.84 | ★ 1.73 |
| Revenue | ★ $787,784,000.00 | $780,567,000.00 |
| Revenue This Year | $9.10 | $8.01 |
| Revenue Next Year | $13.60 | N/A |
| P/E Ratio | ★ $13.05 | $18.94 |
| Revenue Growth | 2.40 | ★ 23.62 |
| 52 Week Low | $10.52 | $23.23 |
| 52 Week High | $22.84 | $50.79 |
| Indicator | UPWK | COLL |
|---|---|---|
| Relative Strength Index (RSI) | 38.30 | 37.32 |
| Support Level | $10.52 | $31.01 |
| Resistance Level | $13.97 | $36.20 |
| Average True Range (ATR) | 0.50 | 1.22 |
| MACD | 0.16 | 0.31 |
| Stochastic Oscillator | 36.62 | 35.08 |
Upwork Inc is a United States-based company that operates an online marketplace that enables businesses to find and work with skilled independent professionals. The company develops platform for hiring and freelancing purposes and connects businesses with AI-enabled talent across every on-demand work type, including freelance, agency, fractional, and payrolled. The business generates revenue from Talent and Clients across the USA, India, Pakistan, the Philippines and the rest of the world. Maximum revenue of the company is derived from Talent segment.
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.